Grunenthal has been granted a patent for compounds that inhibit NaV1.8, which are proposed for use in pain treatment. The patent specifically claims a compound defined by a general formula (I). GlobalData’s report on Grunenthal gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Grunenthal, Human telomerase RT biomarker was a key innovation area identified from patents. Grunenthal's grant share as of June 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US11999699B2 outlines a series of claims related to a novel compound characterized by a general formula (I). The claims detail various substituents and configurations for the compound, including specific groups represented by R1, R2, R3, R4, and R5. Notably, R3 can represent a range of functional groups such as sulfonyl, carbonyl, and various alkyl or aryl groups, while R4 and R5 can independently represent a variety of halogens, alkyl groups, or functional groups like amines and ethers. The patent also specifies that R1 can be a cycloalkyl or heterocycloalkyl group, with particular emphasis on their potential substitutions, including halogens and alkyl groups.
In addition to the structural claims, the patent includes claims for pharmaceutical dosage forms containing the described compounds and methods for treating pain by administering these compounds to subjects in need. The claims suggest that the compounds may have therapeutic applications, particularly in pain management, indicating their potential utility in pharmaceutical formulations. Overall, the patent provides a comprehensive framework for the synthesis and application of these compounds in medicinal chemistry.
To know more about GlobalData’s detailed insights on Grunenthal, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
